Veraxanib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic fibroblast growth factor receptor 2 (FGFR2)-altered solid tumours that have progressed following at least one prior line of systemic therapy and for which there are no satisfactory alternative treatment options.
A companion diagnostic device is required to confirm tumour FGFR2 alteration status prior to initiating treatment with Veraxanib (see section 4.4).
Veraxanib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic fibroblast growth factor receptor 2 (FGFR2)-altered solid tumours that have progressed following at least one prior line of systemic therapy and for which there are no satisfactory alternative treatment options.
A companion diagnostic device is required to confirm tumour FGFR2 alteration status prior to initiating treatment with Veraxanib (see section 4.4).
Veraxanib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic fibroblast growth factor receptor 2 (FGFR2)-altered solid tumours that have progressed following prior therapy and for which there are no satisfactory alternative treatment options.